



By registered post AD / Courier / Post /
~~Speed post / Hand delivery / E-mail / Upload on site~~

February 12, 2026

To,
Department of Corporate Service
BSE Limited,
Registered Office : Floor 25, P. J. Towers,
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.
T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

Subject : Approval of Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2025.

Reference: Centenial Surgical Suture Ltd. | Scrip Code: 531380

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2025.
- 2). Limited Review Report for the quarter and nine months ended December 31, 2025.

You are requested to kindly take the same on your record.

The meeting commenced on 06.30 p.m. & concluded at 06.50 p.m.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**



**Mahima
Bathwal**


Digitally signed by
Mahima Bathwal
Date: 2026.02.12
19:10:18 +05'30'

Mahima BATHWAL

Membership No. ACS A35069

Company Secretary & Compliance Officer

Enclosures : as mentioned above.




®

Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2025

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	1486.42	1345.50	1219.88	4125.53	4020.85	5351.62
II	Other Income	5.12	4.91	0.51	10.22	7.02	12.01
III	Total Revenue (I + II)	1491.54	1350.41	1220.39	4135.75	4027.87	5363.63
IV	Expenses :						
	(a) Cost of Material Consumed	487.32	417.94	416.09	1412.02	1361.89	1656.38
	(b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	40.84	28.85	(91.70)	(4.42)	6.90	66.42
	(d) Employee Benefits Expenses	313.23	315.42	318.99	903.17	881.16	1185.86
	(e) Finance Cost	34.99	46.20	49.76	112.97	155.33	374.55
	(f) Depreciation and Amortisation Expenses	103.56	99.26	110.75	297.96	299.21	425.46
	(g) Other Expenses	491.95	443.94	501.27	1,399.51	1351.40	1816.73
	Total Expenses (IV)	1471.89	1351.61	1305.16	4121.21	4055.89	5525.40
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	19.65	(1.20)	(84.77)	14.54	(28.02)	(161.78)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	19.65	(1.20)	(84.77)	14.54	(28.02)	(161.78)
VIII	Tax Expense :						
	(1) Current Tax	4.95	-	-	3.66	-	-
	(2) Deferred tax	-	-	-	-	-	(15.41)
	Total Tax Expenses	4.95	-	-	3.66	-	(15.41)
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	14.70	(1.20)	(84.77)	10.88	(28.02)	(146.37)
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X - XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	14.70	(1.20)	(84.77)	10.88	(28.02)	(146.37)
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	14.70	(1.20)	(84.77)	10.88	(28.02)	(146.37)
XVI	Earnings Per Equity Share (for Continuing operation) :						
	(a) Basic	0.40	(0.03)	(2.30)	0.30	(0.76)	(4.01)
	(b) Diluted	0.40	(0.03)	(2.30)	0.30	(0.76)	(4.01)
XVII	Earnings Per equity share (for Discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share : (for Discontinued & Continuing operation):						
	Basic (Rs.)	0.40	(0.03)	(2.30)	0.30	(0.76)	(4.01)
	Diluted (Rs.)	0.40	(0.03)	(2.30)	0.30	(0.76)	(4.01)





®

Notes:

- 1). The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on February 12, 2026
- 2). The Company has one reportable business segment "Medical Devices".
- 3). In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors of the Company have carried out a Limited Review of this Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2025.
- 4). The Company's Operation consists only one segment; hence Segment reporting under AS17 is not applicable.
- 5). Previous year figures have been regrouped or reclassified wherever necessary .
- 6). There is no proceeds of public issue, rights issue , preferential issue, qualified institutions placement, etc., therefore statement on the same is not forming part of this results.
- 7). There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- 8). As per the Master Circular dated November 11, 2024 company is not required to give disclosure as per B and C point as not applicable for the current quarter.
- 9). The Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2025 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

for and on behalf of the Board of Directors of
for **CENTENIAL SURGICAL SUTURE LTD.**



VIJAY
KALIDAS
MAJREKAR


Digitally signed by
VIJAY KALIDAS
MAJREKAR
Date: 2026.02.12
18:54:57 +05'30'

Vijay MAJREKAR

Managing Director ~ DIN : 00804808

Place : Mumbai, Maharashtra

Date : February 12, 2026



Independent Auditor's Review Report on Standalone Un-Audited Financial Results of the Company for the Quarter and nine months ended December 31, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements [LODR]) Regulations, 2015, as amended.

Review Report to

The Board of Directors of CENTENIAL SURGICAL SUTURE LTD.

Registered Office : F-29, M.I.D.C., Murbad, Thane 421401. MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Centenial Surgical Suture Limited** (the "Company") for the quarter and nine months ended **December 31, 2025** ("the Statement") prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (*Interim Financial Reporting*) ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and relevant rules issued thereunder, and other accounting principles generally accepted in India, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and SEBI Circulars issued thereunder.
- b. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on **February 12, 2026**, has been prepared in accordance with the recognition and measurement principles of Ind AS 34 and other applicable accounting standards and policies. The management is responsible for the maintenance of adequate accounting records, for safeguarding the assets of the Company, and for preventing and detecting fraud and other irregularities.
- c. Our responsibility is to issue a report on the Statement based on our review. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity**, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of those responsible for financial and accounting matters, and applying analytical and other review procedures. It is substantially less in scope than an audit conducted in accordance with Standards on Auditing and accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, **does not disclose the information required to be disclosed** in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including the manner in which it is required to be disclosed, or that it **contains any material misstatement**.

For **M/s. MAHESH CHANDRA & ASSOCIATES**
CHARTERED ACCOUNTANTS

[Firm Registration No.: 112334W]

Digitally signed by
Vipul Vishnu
Awaghade
Date: 2026.02.12
20:25:51 +05'30'

Vipul Awaghade

Partner

[Membership No.174518]

Date : February 12, 2026
Place : Mumbai, MAHARASHTRA.
UDIN: 26174518HCALEM9615